Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gwen M H E Dackus

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of the National Cancer Institute|August 16, 2021
Response to Klar and AdamsGwen M H E Dackus, Katarzyna Jóźwiak, Michael Hauptmann, et al.
European Journal of Gastroenterology & Hepatology|September 22, 2011
The long-term follow-up of patients with endoscopically diagnosed reflux oesophagitis with specific emphasis to complaintsSusan M L A Loffeld, Gwen M H E Dackus, Ruud J L F Loffeld
Breast Cancer Research and Treatment|August 19, 2016
Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancerMette S van Ramshorst, Margriet van der Heiden-van der Loo, Gwen M H E Dackus, et al.
Breast Cancer Research and Treatment|July 1, 2016
The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancerMette S van Ramshorst, Margriet van der Heiden-van der Loo, Gwen M H E Dackus, et al.
Trials|June 22, 2016
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trialPhilip C Schouten, Gwen M H E Dackus, Serena Marchetti, et al.
Breast Cancer Research and Treatment|October 28, 2020
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancerGwen M H E Dackus, Katarzyna Jóźwiak, Elsken van der Wall, et al.
Journal of the National Cancer Institute|June 8, 2021
Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer PatientsGwen M H E Dackus, Katarzyna Jóźwiak, Gabe S Sonke, et al.
Scientific Reports|September 6, 2022
Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology imagesSuzanne C Wetstein, Vincent M T de Jong, Nikolas Stathonikos, et al.
International Journal of Cancer|February 4, 2021
A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancerJill J J Geenen, Gwen M H E Dackus, Philip C Schouten, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2023
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancerYuwei Wang, Annegien Broeks, Daniele Giardiello, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of the National Cancer Institute|August 16, 2021
Response to Klar and AdamsGwen M H E Dackus, Katarzyna Jóźwiak, Michael Hauptmann, et al.
European Journal of Gastroenterology & Hepatology|September 22, 2011
The long-term follow-up of patients with endoscopically diagnosed reflux oesophagitis with specific emphasis to complaintsSusan M L A Loffeld, Gwen M H E Dackus, Ruud J L F Loffeld
Breast Cancer Research and Treatment|August 19, 2016
Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancerMette S van Ramshorst, Margriet van der Heiden-van der Loo, Gwen M H E Dackus, et al.
Breast Cancer Research and Treatment|July 1, 2016
The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancerMette S van Ramshorst, Margriet van der Heiden-van der Loo, Gwen M H E Dackus, et al.
Trials|June 22, 2016
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trialPhilip C Schouten, Gwen M H E Dackus, Serena Marchetti, et al.
Breast Cancer Research and Treatment|October 28, 2020
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancerGwen M H E Dackus, Katarzyna Jóźwiak, Elsken van der Wall, et al.
Journal of the National Cancer Institute|June 8, 2021
Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer PatientsGwen M H E Dackus, Katarzyna Jóźwiak, Gabe S Sonke, et al.
Scientific Reports|September 6, 2022
Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology imagesSuzanne C Wetstein, Vincent M T de Jong, Nikolas Stathonikos, et al.
International Journal of Cancer|February 4, 2021
A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancerJill J J Geenen, Gwen M H E Dackus, Philip C Schouten, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2023
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancerYuwei Wang, Annegien Broeks, Daniele Giardiello, et al.
Pageof 2